Sign In
Buy AXGN
$40.63
+1.17 (+2.97%)
At Close: Jun 03, 2026
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
09:48am, Tuesday, 08'th Nov 2022
AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
10:35pm, Monday, 07'th Nov 2022 Zacks Investment Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Axogen to Participate at Upcoming Investor Conferences
04:00pm, Thursday, 03'rd Nov 2022
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t
Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.
11:00am, Monday, 31'st Oct 2022 GlobeNewswire Inc.
Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine. Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of
AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know
04:00pm, Thursday, 27'th Oct 2022 Zacks Investment Research
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know
01:32pm, Thursday, 27'th Oct 2022
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022
07:00am, Thursday, 20'th Oct 2022
ALACHUA and TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
01:40pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Here is how Catalyst Pharmaceutical (CPRX) and AxoGen (AXGN) have performed compared to their sector so far this year.
AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?
09:32am, Thursday, 29'th Sep 2022 Zacks Investment Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?
06:47am, Thursday, 29'th Sep 2022
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
07:23am, Monday, 12'th Sep 2022 Benzinga
Gainers
Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in
Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet
01:55pm, Monday, 08'th Aug 2022 Zacks Investment Research
The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?
01:40pm, Monday, 08'th Aug 2022 Zacks Investment Research
Here is how Acadia Healthcare (ACHC) and AxoGen (AXGN) have performed compared to their sector so far this year.
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q2 2022 Results - Earnings Call Transcript
10:13am, Saturday, 06'th Aug 2022
AxoGen, Inc. (NASDAQ:AXGN ) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO C
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
